Partner Headlines - NPSP

  1. Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion

    GuruFocus
  2. 10 Biotech Stories You Might've Missed This Week

    Benzinga
  3. Meet 5 Top Medical Stocks Making Waves This Week

    IBD
  4. Wall Street's Wheelings And Dealings

    Benzinga
  5. UPDATE: Barclays Capital Downgrades NPS Pharmaceuticals After ...

    Benzinga
  6. Shire Agrees To Acquire NPS Pharmaceuticals

    IBD
  7. Mid-Day Market Update: Foundation Medicine Shares Jump Following ...

    Benzinga
  8. Mid-Morning Market Update: Markets Tumble; Shire To Acquire NPS ...

    Benzinga
  9. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  10. Benzinga's Volume Movers

    Benzinga
  11. Morning Market Losers

    Benzinga
  12. Morning Market Gainers

    Benzinga
  13. UPDATE: Jefferies Raises Price Target On NPS Pharmaceuticals ...

    Benzinga
  14. Benzinga's Top Downgrades

    Benzinga
  15. Benzinga's Top #PreMarket Losers

    Benzinga
  16. Benzinga's Top #PreMarket Gainers

    Benzinga
  17. Canaccord Genuity Downgrades NPS Pharmaceuticals To Hold

    Benzinga
  18. US Stock Futures Signal Higher Start On Wall Street

    Benzinga
  19. Must Watch Stocks for January 12, 2015

    Benzinga
  20. Benzinga's Weekend M&A Chatter

    Benzinga
  21. Shire To Acquire NPS Pharmaceuticals for $5.2 Billion

    Benzinga
  22. What Investors Should Expect From Rockwell Medical's Next FDA ...

    Benzinga
  23. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  24. UPDATE: Barclays Capital Initiates Coverage On NPS Pharmaceuticals ...

    Benzinga
  25. Benzinga's M&A Chatter for Monday January 5, 2015

    Benzinga
  26. Report: NPS Pharmaceuticals Headed For Block

    Benzinga
  27. New Biotech ETF From ALPS

    Benzinga
  28. Benzinga's M&A Chatter for Wednesday December 17, 2014

    Benzinga
  29. NPS Pharmaceuticals Spikes 19% Amid Shire Bid Report

    Benzinga
  30. Morning Market Losers

    Benzinga
  31. Benzinga's Top #PreMarket Losers

    Benzinga
  32. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  33. Benzinga's Weekend M&A Chatter

    Benzinga
  34. Technology Stocks Down As Rest Of The Market Starts Week Flat

    Benzinga
  35. Terex Falls After Lowered Earnings Forecast; Avanir Pharmaceuticals ...

    Benzinga
  36. NASDAQ Tumbles 1.1%; Alere Shares Surge Following Proposed $46/Share ...

    Benzinga
  37. Markets Fall; Cognizant To Acquire TriZetto For $2.7 Billion

    Benzinga
  38. Morning Market Losers

    Benzinga
  39. Benzinga's Top #PreMarket Losers

    Benzinga
  40. US Stock Futures Flat Ahead Of Economic Data

    Benzinga
  41. NPS Pharma Stock Trading Halted Today; FDA Advisory Committee ...

    Benzinga
  42. FDA says NPS drug is effective

    IBD
  43. Stocks Gain As Oil, Euro Continue Sharp Sell Off

    Benzinga
  44. Lands' End Jumps On Strong Quarterly Earnings; GT Advanced Technologies ...

    Benzinga
  45. U.S. Stocks Rise; Palo Alto Networks Shares Surge On Upbeat Revenue

    Benzinga
  46. Markets Edge Lower; Krispy Kreme Doughnuts Profit Misses Estimates

    Benzinga
  47. Benzinga's Volume Movers

    Benzinga
  48. Morning Market Movers

    Benzinga
  49. FDA Posts Briefing Materials For Advisory Committee Meeting ...

    Benzinga
  50. NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients ...

    Benzinga
  51. Valeant Goes For Allergan; Analyst Touts Shire Option

    IBD
  52. Mid-Afternoon Market Update: Markets Turn Back As SolarCity Hangs ...

    Benzinga
  53. Mid-Day Market Update: Keurig Green Mountain Jumps On Upbeat ...

    Benzinga
  54. Mid-Morning Market Update: Markets Gain; Wendy's Profit Beats ...

    Benzinga
  55. Morning Market Losers

    Benzinga
  56. UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals ...

    Benzinga
  57. Benzinga's Top Initiations

    Benzinga
  58. UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

    Benzinga
  59. NPS Pharma Finds Big Success In Tiny Markets

    IBD
  60. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  61. NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara ...

    Benzinga
  62. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  63. Mid-Afternoon Market Update: Markets Mixed as Tesla Shares Remain ...

    Benzinga
  64. NPS Pharma Says Data from STEPS 2 Trial of Gattex Supports Long-Term ...

    Benzinga
  65. Mid-Afternoon Market Update: Markets Green as Spirit Airlines ...

    Benzinga
  66. Mid-Day Market Update: Micron Shares Tumble On Downbeat Profit; ...

    Benzinga
  67. Mid-Morning Market Update: Markets Rise; JPMorgan Posts Upbeat ...

    Benzinga
  68. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  69. NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary ...

    Benzinga
  70. UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  71. Benzinga's Top Initiations

    Benzinga
  72. NPS Pharma Says sNDA Submitted for Gattex STEPS 2 Data, Shows ...

    Benzinga
  73. Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN

    GuruFocus
  74. UPDATE: J.P. Morgan Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  75. Benzinga's Top Initiations

    Benzinga
  76. UPDATE: Oppenheimer Raises PT on NPS Pharmaceuticals Following ...

    Benzinga
  77. Market Wrap for Friday, August 9: Stocks Close Lower To End Week

    Benzinga
  78. NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth ...

    YCharts
  79. You Can Expect More Insider Trading in Pharma Stocks: Here's ...

    YCharts
  80. FDA Approves NPS Gattex for Injection for Some SBS Patients

    Benzinga
  81. NPS Pharma Shares Moving Lower Amid FDA Approval of Gattex

    Benzinga
  82. NPS Pharma Publishes Pivotal Phase 3 Study of Gattex in Short ...

    Benzinga
  83. NPS Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  84. Benzinga Mid-Afternoon Market Update

    Benzinga
  85. Benzinga Mid-Day Market Update

    Benzinga
  86. Benzinga Mid-Morning Market Update

    Benzinga
  87. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  88. FDA Advisory Committee Unanimously Recommends Approval of Gattex® ...

    Benzinga
  89. Benzinga Mid-Day Market Update

    Benzinga
  90. Benzinga Mid-Afternoon Market Update

    Benzinga
  91. Benzinga Mid-Morning Market Update

    Benzinga
  92. UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight ...

    Benzinga
  93. Benzinga's Top Pre-Market Gainers

    Benzinga
  94. NPS Pharma Expects to File Natpara BLA in Mid 2013

    Benzinga
  95. Revestive Receives European Marketing Authorization for the Treatment ...

    Benzinga
  96. NPS Pharma Says Gattex Meeting October 16th

    Benzinga
  97. Biotechs With Upcoming PDUFA Dates

    Benzinga
  98. NPS Pharmaceuticals (NPSP) Gains 10.8% as Short Bowel Drug Moves ...

    MarketIntelligenceCenter
  99. Social Media Outlook for Friday June 22 (DRI, NPSP, R, GS)

    Benzinga
  100. Benzinga's Top Pre-Market Gainers

    Benzinga
Trading Center